

Appln No. 10/680,818

Amdt date March 26, 2007


Reply to Office action of September 26, 2006

Amendments to the Specification:

On page 3, line 19, please amend the paragraph to read as follows:

"The present invention provides methods for labeling structures, including .beta.-amyloid plaques and neurofibrillary tangles, in vivo and in vitro, and comprises contacting a compound of formula (I):

with mammalian tissue. In formula (I), R₁ is selected from the group consisting of --C(O)-alkyl, --C(O)-alkylenyl-R₄, --C(O)O-alkyl, --C(O)O-alkylenyl R₄, --C=C(CN).sub.2-alkyl, --C=C(CN)₂-alkylenyl-R₄,




R₄ is a radical selected from the group consisting of alkyl, substituted alkyl, aryl and substituted aryl; R₅ is a radical selected from the group consisting of --NH₂, --OH, --SH, --NH-alkyl, --NHR₄, --NH-alkylenyl-R₄, --O-alkyl, --O-alkylenyl-R₄, --S-alkyl, and --S-alkylenyl-R₄; R₆ is a radical selected from the group consisting of --CN, --COOH, --C(O)O-alkyl, --C(O)O-alkylenyl-R₄, --C(O)-alkyl, --C(O)-alkylenyl-R₄, --C(O)-halogen, --C(O)NH₂, --C(O)NH-alkyl, --C(O)NH-alkylenyl-R₄; R₇ is a radical selected from the group consisting of O, NH, and S; and R₈ is N, O or S. R₈ is N.

On page 4, line 18, please amend the paragraph to read as follows:

" In still another embodiment, the invention is directed to a composition comprising a compound of formula (I):

Appln No. 10/680,818
 Amdt date March 26, 2007
 Reply to Office action of September 26, 2006

R₁ is selected from the group consisting of --C(O)-alkyl, --C(O)-alkylenyl-R₄, --C(O)O-alkyl, --C(O)O-alkylenyl-R₄, --C=C(CN).sub.2-alkyl, --C=C(CN)₂-alkylenyl-R₄,



R₄ is a radical selected from the group consisting of alkyl, substituted alkyl, aryl and substituted aryl; R₅ is a radical selected from the group consisting of --NH₂, --OH, --SH, --NH-alkyl, --NHR₄, --NH-alkylenyl-R₄, --O-alkyl, --O-alkylenyl-R₄, --S-alkyl, and --S-alkylenyl-R₄; R₆ is a radical selected from the group consisting of --CN, --COOH, --C(O)O-alkyl, --C(O)O-alkylenyl-R₄, --C(O)-alkyl, --C(O)-alkylenyl-R₄, --C(O)-halogen, --C(O)NH₂, --C(O)NH-alkyl, --C(O)NH-alkylenyl-R₄; R₇ is a radical selected from the group consisting of O, NH, and S; ~~R₈ is N, O or S;~~ R₈ is N; R₂ is selected from the group consisting of alkyl and alkylenyl-R₅ and R₃ is alkylenyl-R₅, and R₅ is selected from the group consisting of --OH, --OTs, halogen, spiperone, spiperone ketal, and spiperone-3-yl, or R₂ and R₃ together form a heterocyclic ring, optionally substituted with at least one radical selected from the group consisting of alkyl, alkoxy, OH, OTs, halogen, alkylenyl-R₅ carbonyl, spiperone, spiperone ketal and spiperone-3-yl. One or more of the hydrogen, halogen or carbon atoms can optionally be replaced with a radiolabel.

On page 7, line 16, please replace the second pictured chemical structure with the following corrected chemical structure:


Query

On page 7, line 15, please amend the paragraph to read as follows:

SK
7/19/07

"The present invention is directed to methods for labeling structures such as β -amyloid plaques and neurofibrillary tangles in vivo and in vitro. The methods all involve contacting a compound of formula (I):

with mammalian tissue. In formula (I), R_1 is selected from the group consisting of --C(O)-alkyl, -C(O)-alkylenyl- R_4 --C(O)O-alkyl, --C(O)O-alkylenyl- R_4 --C=C(CN)₂-alkyl, --C=C(CN)₂-alkylenyl- R_4 ,



R_4 is a radical selected from the group consisting of alkyl, substituted alkyl, aryl and substituted aryl. R_5 is a radical selected from the group consisting of --NH₂, --OH, --SH, --NH-alkyl, --NHR₄, --NH-alkylenyl- R_4 , --O-alkyl, --O-alkylenyl- R_4 , --S-alkyl, and --S-alkylenyl- R_4 . $R_{sub.6}$ is a radical selected from the group consisting of --CN, --COOH, --C(O)O-alkyl, --C(O)O-alkylenyl- R_4 , --C(O)-alkyl, --C(O)-alkylenyl- R_4 , --C(O)-halogen, --C(O)NH₂, --C(O)NH-alkyl, --C(O)NH-alkylenyl- R_4 . R_7 is a radical selected from the group consisting of O, NH, and S. ~~R_8 is N, O or S.~~ R_8 is N.